Publications in collaboration with researchers from Beckman Research Institute (10)

2024

  1. An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma

    European Journal of Haematology, Vol. 113, Núm. 5, pp. 593-605

  2. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840

2022

  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

  2. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  2. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    The Lancet, Vol. 398, Núm. 10301, pp. 665-674

2020

  1. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis

    JAMA Oncology, Vol. 6, Núm. 11, pp. 1759-1765

2016

  1. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557